ZLAB | Ticker Profile - Titan Protect

ZLAB

Zai Lab Limited

Healthcare · Biotechnology · NGM

$16.62

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-10.70

Based on estimated future earnings — lower means cheaper

Rev Growth

-6.5%

Year-over-year revenue change

Profit Margin

-39.3%

How much profit the company keeps from each dollar of revenue

ROE

-24.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$32.24

+94% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 12 analysts covering this stock

About Zai Lab Limited

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

https://www.zailaboratory.com

Country: China Employees: 1,784 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.315

Positive but modest risk-adjusted returns

Kelly Fraction

0.0206

Modest edge detected — smaller position warranted

Calmar Ratio

0.023

Drawdown risk outweighs the returns — higher risk profile

Annual Return

1.5%

Historical annualised return based on price data

Max Drawdown

-62.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

178

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.85

Less volatile than the market — more defensive

52W High

$44.34

63% below the year high

52W Low

$15.96

4% above the year low

Avg Volume

783,644

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.7%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.70

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

35.03

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.40

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.84

Like current ratio but excludes inventory — stricter test

Gross Margin

8.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-69.7%

Profit from core operations before interest and tax

Free Cash Flow

$-73,355,376

Negative — the business is spending more than it generates

Revenue (TTM)

$453M

Total revenue over the last 12 months

Net Income

$-178,115,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$52.00

Target Median

$32.24

Target Low

$21.60

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go